FDA Approves Torisel for Renal Cell Carcinoma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

FDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa

ROCKVILLE, Maryland—FDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa. Median overall survival was 10.9 months for Torisel patients vs 7.3 months for interferon patients. Progression-free survival increased from 3.1 months with interferon to 5.5 months with Torisel. The combination of Torisel and interferon did not result in a significant increase in overall survival, compared with interferon alone. Look for a complete report on the approval in the July issue of ONI.

Articles in this issue
ACS Launches Major Epidemiology Study
Pt Selection Key to Radioembolization of Liver Ca's
Million Dollar Gotham Prize Announced
Diagnostic Dilemma: GI Disease
Velcade/Doxil Approved for Relapsed or Refractory Multiple Myeloma Pts
Junovan Fails to Win ODAC Nod for Osteosarcoma Treatment
Surveillance Colonoscopy Guidelines Not Being Followed
Removing Stage IV Primary May Cut Mortality
Nuclear Export Inhibitors Testing Moving Forward
ODAC: orBec Yields No 'Substantial Efficacy' in GI GVHD
Gene Expression Profiles of HCC Revealed on CT Scans
Best Measure of Lung Cancer Screening: Curability or Mortality?
New Labeling Restrictions for ESAs: ODAC
Value-Based Competition Key to Healthcare Reform
Cranial Irradiation Prevents CNS Metastases in SCLC

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 1st 2025
Podcast

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

Potential Biomarker May Predict Outcomes/Response in RCC

Potential Biomarker May Predict Outcomes/Response in RCC

Kyle Doherty
July 18th 2025
Article

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.